SLAMF7 and B-cell chronic lymphocytic leukemia: Consequently, high levels of SLAMF1/CD150 and SLAMF7/CD319 may lead to lesser therapeutic efficacy of the BCR pathway antagonists such as ibrutinib (or other Bruton kinase inhibitors) in CLL patients with mutated IGHV.